Validating the European LeukemiaNet 2022 Guidelines in a Middle Eastern Acute Myeloid Leukemia Cohort: Correlation With Survival Outcomes and Comparison to ELN 2017.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
171 patients receiving intensive chemotherapy (IC), ELN2022 was even more discriminative (EFS C index 0.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Consistent with Western findings, neither ELN system was validated in our subgroup of 28 nonintensively treated patients (for ELN2022, adverse risk had the longest median EFS and OS). [CONCLUSION] ELN2022 was an independent predictor of survival in a Middle Eastern AML cohort, particularly for patients receiving IC, validating this prognostic tool in an understudied population.
[BACKGROUND] The European LeukemiaNet (ELN) guidelines are widely used for risk stratification in acutemyeloid leukemia (AML), but validation in non Western patients remains limited.
- p-value P < .001
APA
Alshemmari SH, AlSarraf A, et al. (2026). Validating the European LeukemiaNet 2022 Guidelines in a Middle Eastern Acute Myeloid Leukemia Cohort: Correlation With Survival Outcomes and Comparison to ELN 2017.. Clinical lymphoma, myeloma & leukemia. https://doi.org/10.1016/j.clml.2026.02.001
MLA
Alshemmari SH, et al.. "Validating the European LeukemiaNet 2022 Guidelines in a Middle Eastern Acute Myeloid Leukemia Cohort: Correlation With Survival Outcomes and Comparison to ELN 2017.." Clinical lymphoma, myeloma & leukemia, 2026.
PMID
41796448 ↗
Abstract 한글 요약
[BACKGROUND] The European LeukemiaNet (ELN) guidelines are widely used for risk stratification in acutemyeloid leukemia (AML), but validation in non Western patients remains limited.
[MATERIALS AND METHOD] This retrospective study of 227 newly diagnosed AML patients from the Kuwait Cancer Control Center assessed the 2022 and 2017 ELN risk classification systems and their impact on event-free survival (EFS) and overall survival (OS), add ressing the need for diverse population data in AML prognostication.
[RESULTS] Compared to ELN2017, ELN2022 reclassified 14% of patients. Outcomes were effectively discriminated by both ELN2017 (EFS C index 0.607, log rank P < .001; OS C index 0.591, P < 001) and ELN2022 (EFS C index 0.607, P < .001; OS C index 0.590, P < .001). Among 171 patients receiving intensive chemotherapy (IC), ELN2022 was even more discriminative (EFS C index 0.650; OS C index 0.637). Multivariable analyses confirm ELN2022 as an independent predictor of outcomes for the full cohort (EFS 2df Wald P < .001; OS P = .004) and IC subset (EFS P < .001; OS P = .001). Consistent with Western findings, neither ELN system was validated in our subgroup of 28 nonintensively treated patients (for ELN2022, adverse risk had the longest median EFS and OS).
[CONCLUSION] ELN2022 was an independent predictor of survival in a Middle Eastern AML cohort, particularly for patients receiving IC, validating this prognostic tool in an understudied population.
[MATERIALS AND METHOD] This retrospective study of 227 newly diagnosed AML patients from the Kuwait Cancer Control Center assessed the 2022 and 2017 ELN risk classification systems and their impact on event-free survival (EFS) and overall survival (OS), add ressing the need for diverse population data in AML prognostication.
[RESULTS] Compared to ELN2017, ELN2022 reclassified 14% of patients. Outcomes were effectively discriminated by both ELN2017 (EFS C index 0.607, log rank P < .001; OS C index 0.591, P < 001) and ELN2022 (EFS C index 0.607, P < .001; OS C index 0.590, P < .001). Among 171 patients receiving intensive chemotherapy (IC), ELN2022 was even more discriminative (EFS C index 0.650; OS C index 0.637). Multivariable analyses confirm ELN2022 as an independent predictor of outcomes for the full cohort (EFS 2df Wald P < .001; OS P = .004) and IC subset (EFS P < .001; OS P = .001). Consistent with Western findings, neither ELN system was validated in our subgroup of 28 nonintensively treated patients (for ELN2022, adverse risk had the longest median EFS and OS).
[CONCLUSION] ELN2022 was an independent predictor of survival in a Middle Eastern AML cohort, particularly for patients receiving IC, validating this prognostic tool in an understudied population.